GC007g

Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) and patient screening underway in Phase 1b portion Expect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the third quarter of 2023 On track to submit US IND filing for planned Phase 1 trial of GC012F in refractory systemic lupus erythematosus (rSLE) in 2023 Dosed multiple patients in the investigator-initiated trial (IIT) in China evaluating GC012F in rSLE Closed a private placement of ordinary shares and warrants to generate $100 million upfront and up to $50 million tied to exercise of warrants, extending cash runway into the second half of 2026 Management to host conference call at 8:00 a.m. ET today SAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today reported second quarter unaudited financial results for the period ended June 30, 2023, and provided corporate updates. “We are delighted with the significant milestones achieved in the past few months across our reprioritized pipeline. Encouraged by the latest impressive clinical data for GC012F across hematological indications presented at ASCO and EHA, we continue to focus on the development and expansion of this highly-competitive, next-generation CAR-T product candidate. The Phase 1b part of the RRMM US IND trial has commenced as patient screening is underway. We also continue to explore the potential of GC012F in early line, and look forward to presenting longer follow-up data from the ongoing clinical IIT evaluating GC012F in newly diagnosed multiple myeloma (NDMM) at an upcoming international medical conference in September,” said Dr. William (Wei) Cao, founder, Chairman and CEO of Gracell. “The expansion into the autoimmune diseases is also a priority and we are on track to US IND in 2023 to conduct a Phase 1 trial for GC012F in rSLE. We have dosed multiple patients in the rSLE IIT and anticipate that topline data from this ongoing study will be available during the first half of 2024.” Dr. Cao continued, “With the completion of a private placement financing of $100 million upfront and up to $50 million upon warrant exercise led by well-regarded healthcare investors, we strengthened our balance sheet and extended our runway into the second half of 2026.” Pipeline Summary FasTCAR-T GC012F: Autologous BCMA/CD19 dual targeting CAR-T therapy candidate utilizing FasTCAR next-day manufacturing to significantly shorten patient wait times and enhance cell fitness FasTCAR-T GC012F in relapsed refractory multiple myeloma (RRMM): Initiated the Company-sponsored Phase 1b/2 clinical trial in U.S. (NCT05850234) evaluating GC012F in RRMM Patient recruitment has commenced in the Phase 1b part of the trial On track to initiate the Company-sponsored Phase 1/2 clinical trial in China evaluating GC012F in RRMM expected in the third quarter of 2023 Presented long-term follow-up data from a multicenter IIT at ASCO 2023 Annual Meeting and EHA2023 Congress demonstrating deep and durable responses Among 29 treated RRMM patients, GC012F showed 93.1% overall response rate (ORR), 82.8% stringent complete response (sCR) rate, 100% minimal residual disease negativity (MRD-), and a median progression free survival (mPFS) of 38.0 months (95% CI: 11.8-NR) as of the data cutoff date April 12, 2023 FasTCAR-T GC012F in newly diagnosed multiple myeloma (NDMM): Clinical data update with additional patients and longer follow-up from ongoing IIT to be presented in the third quarter of 2023 FasTCAR-T GC012F in B-cell non-Hodgkin’s lymphoma (B-NHL): Presented updated clinical data from an IIT at ASCO 2023 Annual Meeting and EHA2023 Congress Among nine treated patients and as of the data cutoff date April 12, 2023, GC012F showed 100% ORR and 77.8% complete response (CR) rate at 3 months, and 66.7% CR rate at 6 months. All nine patients are classified as relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the most challenging subtype of B-NHL. FasTCAR-T GC012F in refractory systemic lupus erythematosus(rSLE) BCMA/CD19 dual-targeting design aims to achieve more effective elimination of antibody-secreting cells, in comparison to CD19 single-targeting CAR-T IIT evaluating GC012F in rSLE underway in China Patient enrollment and dosing underway Anticipate to share initial data in the first half of 2024 On track to submit US IND filing for planned Phase 1 trial in 2023 GC007g for the treatment of B-ALL: Allogeneic CD19-targeted CAR-T cell therapy, derived from human leukocyte antigen (HLA) matched donor, for the treatment of relapsed/refractory b-cell acute lymphoblastic leukemia (r/r B-ALL) patients who failed transplant and may not be eligible for autologous CAR-T therapy. Phase 1 data presented at EHA2023 Congress highlighted 100% MRD- complete response or complete response with/without complete hematologic recovery (CR/CRi) Registrational Phase 2 trial ongoing in China SMART CART™ GC506: With unique construct to take advantage of the suppressive tumor microenvironment (TME) and effectively combat solid tumors, SMART CART™ is designed to enhance CAR-T cell proliferation and duration of killing, and to resist exhaustion with improved persistence of CAR-T cells. Commenced an IIT in China for GC506 in Claudin18.2 positive solid tumors Reprioritization of Pipeline: The Company completed a strategic review of its clinical pipeline and will prioritize its resources on the clinical development of its most innovative product candidates that have the best-in-class potential, such as dual-targeting FasTCAR-T GC012F. The Company expects to incur minimal expenses related to program discontinuations. PIPE Financing On August 10, 2023, the Company closed a private placement of 138,900,000 ordinary shares (equivalent to 27,780,000 of the Company’s American depositary shares (“ADSs”)) and warrants to purchase up to 44,802,870 ordinary shares (equivalent to 8,960,574 ADSs), exercisable at the election of the investors within 24 months after closing. The Company has received $100 million in proceeds from the private placement of ordinary shares, and will receive up to an additional $50 million if the warrants are fully exercised. The financing included participation from the high-quality healthcare investors and was led by Vivo Capital, with participation from new and existing shareholders including Adage Capital Partners LP, Exome Asset Management, Janus Henderson Investors, Logos Capital, OrbiMed, Pivotal Life Sciences, RA Capital Management and TCGX, among others. The aggregate proceeds from this financing, combined with current cash, cash equivalents, is expected to be sufficient to fund the current operating plan into the second half of 2026. Financial Results for Second Quarter Ended June 30, 2023 As of June 30, 2023, the Company had RMB1,188.0 million (US$163.8 million) in cash and cash equivalents and short-term investments. In addition, the Company had short-term borrowings and current portion of long-term borrowings of RMB103.0 million (US$14.2 million) and long-term borrowings of RMB40.0 million (US$5.5 million). Net loss attributable to ordinary shareholders for the three months ended June 30, 2023 was RMB146.9 million (US$20.3 million), compared to RMB146.3 million for the corresponding prior year period. Research and Development Expenses Research and development expenses for the three months ended June 30, 2023 were RMB103.8 million (US$14.3 million), compared to RMB117.1 million in the corresponding prior year period. The decrease was primarily due to the decreased spending on research, development, clinical trials and payroll. Administrative Expenses Administrative expenses for the three months ended June 30, 2023 were RMB37.4 million (US$5.2 million), compared to RMB28.8 million for the corresponding prior year period. The increase was primarily driven by an increase in professional service fees as well as an increase in share-based compensation expenses. As of June 30, 2023, 340,655,139 ordinary shares (excluding 22,735,527 ordinary shares issued to depositary bank as of June 30, 2023, for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under our share incentive plans), par value of US$0.0001 per share, were issued and outstanding. As of June 30, 2023, 19,529,166 options were granted and 14,852,668 options were outstanding, and 5,038,056 restricted share units (“RSUs”) were granted under our employee stock option plan. Immediately following the close of private placement transaction, 479,555,139 ordinary shares, par value of US$0.0001 per share, were issued and outstanding. Each of our ADS represents five ordinary shares. Conference Call and Webcast Details: Monday, August 14, 2023 @ 8:00 am ET Investor domestic dial-in: (800) 715-9871 Investor international dial-in: (646) 307-1963 Conference ID: 2527305 Live webcast link: A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days. About GC012F GC012F is Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy, which aims to transform cancer and autoimmune disease treatment by driving fast, deep and durable responses with improved safety profile. GC102F is currently being evaluated in clinical studies in multiple hematological cancers as well as autoimmune diseases, and has demonstrated a consistently strong efficacy and safety profile. Gracell has initiated a Phase 1b/2 trial evaluating GC012F for the treatment of relapsed/refractory multiple myeloma in the US and expects to initiate a Phase 1/2 clinical trial in China. Gracell has also commenced an investigator-initiated trial evaluating GC012F for the treatment of refractory systemic lupus erythematosus (rSLE). About FasTCAR Introduced in 2017, FasTCAR is Gracell's revolutionary next-day autologous CAR-T cell manufacturing platform. FasTCAR is designed to lead the next generation of cell therapy for cancer and autoimmune diseases, and improve outcomes for patients by enhancing CAR-T cell fitness, reducing costs, and enabling more patients to access critical CAR-T treatment. FasTCAR drastically shortens cell production from weeks to overnight, potentially reducing patient wait times and probability for their disease to progress. Furthermore, FasTCAR T-cells appear younger than traditional CAR-T cells, making them more proliferative and effective at killing cancer cells. In November 2022, FasTCAR was named the winner of the Biotech Innovation category of the 2022 Fierce Life Sciences Innovation Awards for its ability to address major industry obstacles. About Gracell Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CAR™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. The lead candidate BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in the clinical studies for the treatment of multiple myeloma, B-NHL and systemic lupus erythematosus (SLE). For more information on Gracell, please visit and follow @GracellBio on LinkedIn. Exchange Rate Information This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars are made at a rate of RMB 7.2513 to US$1.00, the rate in effect as of June 30, 2023 published by the Federal Reserve Board. Cautionary Note Regarding Forward-Looking Statements Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “look forward to,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled “Risk Factors” in Gracell’s most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in Gracell’s subsequent filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof. Gracell specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date. Unaudited Condensed Consolidated Balance Sheets (All amounts in thousands, except for share and per share data) As of December 31, As of June 30, 2022 2023 RMB RMB US$ ASSETS Current assets: Cash and cash equivalents 1,454,645 1,184,430 163,340 Short-term investments 3,559 3,574 493 Prepayments and other current assets 37,551 59,402 8,192 Total current assets 1,495,755 1,247,406 172,025 Property, equipment and software, net 123,126 106,698 14,714 Operating lease right-of-use assets 21,546 12,896 1,778 Other non-current assets 15,849 10,886 1,501 TOTAL ASSETS 1,656,276 1,377,886 190,018 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accruals and other current liabilities 85,991 75,580 10,422 Short-term borrowings 104,600 90,000 12,412 Operating lease liabilities, current 17,545 12,472 1,720 Amounts due to a related party 4,662 2,760 381 Current portion of long-term borrowings 7,844 13,004 1,793 Total current liabilities 220,642 193,816 26,728 Operating lease liabilities, non-current 6,485 2,542 351 Long-term borrowings 46,505 39,958 5,510 Other non-current liabilities 6,879 4,851 669 TOTAL LIABILITIES 280,511 241,167 33,258 Shareholders’ equity: Ordinary shares 223 225 31 Additional paid-in capital 2,927,295 2,942,348 405,768 Accumulated other comprehensive income 73,528 118,089 16,285 Accumulated deficit (1,625,281 ) (1,923,943 ) (265,324 ) Total shareholders’ equity 1,375,765 1,136,719 156,760 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 1,656,276 1,377,886 190,018 Unaudited Condensed Consolidated Statements of Comprehensive Loss (All amounts in thousands, except for share and per share data) For the three months ended June 30, For the six months ended June 30, 2022 2023 2022 2023 RMB RMB US$ RMB RMB US$ Expenses Research and development expenses (117,058 ) (103,803 ) (14,315 ) (238,895 ) (241,309 ) (33,278 ) Administrative expenses (28,766 ) (37,350 ) (5,151 ) (66,656 ) (66,438 ) (9,162 ) Loss from operations (145,824 ) (141,153 ) (19,466 ) (305,551 ) (307,747 ) (42,440 ) Interest income 2,702 5,268 726 5,198 19,895 2,744 Interest expense (1,657 ) (1,704 ) (235 ) (3,082 ) (3,360 ) (463 ) Other income 1,797 5,907 815 1,940 6,538 902 Foreign exchange loss, net (3,324 ) (11,017 ) (1,519 ) (3,395 ) (9,736 ) (1,343 ) Others, net 1 (4,225 ) (583 ) 2 (4,226 ) (583 ) Loss before income tax (146,305 ) (146,924 ) (20,262 ) (304,888 ) (298,636 ) (41,183 ) Income tax expense — (10 ) (1 ) — (26 ) (4 ) Net loss attributable to Gracell Biotechnologies Inc.’s ordinary shareholders (146,305 ) (146,934 ) (20,263 ) (304,888 ) (298,662 ) (41,187 ) Other comprehensive income Foreign currency translation adjustments, net of nil tax 82,028 62,443 8,611 75,591 44,561 6,145 Total comprehensive loss attributable to Gracell Biotechnologies Inc.’s ordinary shareholders (64,277 ) (84,491 ) (11,652 ) (229,297 ) (254,101 ) (35,042 ) Weighted average number of ordinary shares used in per share calculation: —Basic 338,355,742 341,336,375 341,336,375 338,244,214 339,951,916 339,951,916 —Diluted 338,355,742 341,336,375 341,336,375 338,244,214 339,951,916 339,951,916 Net loss per share attributable to Gracell Biotechnologies Inc.’s ordinary shareholders —Basic (0.43 ) (0.43 ) (0.06 ) (0.90 ) (0.88 ) (0.12 ) —Diluted (0.43 ) (0.43 ) (0.06 ) (0.90 ) (0.88 ) (0.12 ) Media contact: Marvin Tang marvin.tang@gracellbio.com Investor contact: Gracie Tong gracie.tong@gracellbio.com

Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123) studies for patients with r/r B-cell ALL, r/r B-cell NHL and r/r AML, respectively Preclinical data presented on HBB gene correction of sickle cell mutation & TALE Base Editors (TALE-BE) at ISCT 2023 annual event Appointment of Cécile Chartier, Ph.D., as Director to Cellectis’ Board of Directors Cash position1 of $89 million as of June 30, 2023. Cash runway into Q3 2024 Full financial statements for the second quarter of 2023 will be released in the coming days Conference call scheduled for 8AM ET/2PM CET on August 4, 2023 NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided business updates and preliminary financial results for the six-month period ending June 30, 2023. Full report of the financial results for the second quarter of 2023 will be released in the coming days. “We are proud of our team and the strong execution this quarter. Our clinical data presented for UCART22 at the European Hematology Association (EHA) were positive for patients with r/r B-ALL who have failed multiple lines of treatment including multi-agent chemoimmunotherapy, CD19 directed CAR T-cell therapy, and allogeneic stem cell transplant. We are looking forward to releasing new data later this year on our UCART22 product candidate manufactured in-house,” said André Choulika, Ph.D., Chief Executive Officer at Cellectis. “In addition, we have made progress with our pipeline in 2023 and continue to focus on our core clinical trials BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123). This quarter, Cellectis presented an encore of the clinical data on the AMELI-01 clinical trial at the American Society of Gene and Cell Therapy (ASGCT) 2023 annual meeting. These preliminary data support the continued administration of UCART123 after FCA lymphodepletion in patients with r/r AML. Cellectis’ innovation team also presented preclinical data on a gene editing process to develop a bona fide HBB gene correction of sickle cell mutation, and a comprehensive analysis to better design efficient TALE Base Editors (TALE-BE) at the International Society for Cell and Gene Therapy (ISCT) 2023 annual meeting. These achievements showcase once more the power of our gene-editing platform and our TALEN®, the technology of choice for therapeutic gene editing, and that we are continuing to deliver constant breakthrough innovation to treat diseases with unmet medical needs. Despite an unprecedented challenging market environment for cell and gene therapy companies, Cellectis remains focused in its mission to develop innovative cancer therapy product candidates.” Pipeline Highlights UCART Clinical Development Programs BALLI-01 (evaluating UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and is being evaluated in patients with r/r B-ALL in the BALLI-01 Phase 1/2a clinical study. On June 9, Cellectis presented updated clinical and translational data at the European Hematology Association (EHA). These data support the preliminary safety and efficacy of UCART22 in a heavily pretreated r/r B-ALL population. UCART22 is currently the most advanced allogeneic CAR T-cell product in development for r/r B-ALL. In the poster presented at EHA, Cellectis included data from patients who received UCART22 after fludarabine, cyclophosphamide (FC) and FC with alemtuzumab (FCA) lymphodepletion (LD). Compared to the clinical update on BALLI-01 at ASH 2021, we have included data from six additional patients who received UCART22 at dose level 3 (DL3), as of the December 31, 2022 data cutoff. UCART22 administered after FC or FCA LD regimen was well tolerated. No dose limiting toxicities (DLTs) nor immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. For FCA-dose level 3, 50% of the six patients responded. Host lymphocytes remained suppressed through Day 28 for all patients who received FCA LD. Peak ferritin levels correlated with UCART22 cell expansion and cytokine release syndrome (CRS). UCART22 continues to be well tolerated, with no treatment emergent serious adverse events (TESAEs) or DLTs reported. UCART22 cell expansion was detected in 9 of 13 patients in the FCA LD arm and associated with clinical activity. The BALLI-01 study is currently enrolling patients after FCA LD with Cellectis’ in-house manufactured product. The next data set is expected to be released later this year. NATHALI-01 (evaluating UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) UCART20x22 is Cellectis’ first dual allogeneic CAR T-cell product candidate targeting both CD20 and CD22 and is being evaluated in patients with r/r B-NHL in the NATHALI-01 Phase 1/2a clinical study2. The NATHALI-01 clinical study is ongoing. Cellectis expects to provide first-in-human data later this year.AMELI-01 (evaluating UCART123) in relapsed or refractory acute myeloid leukemia (r/r AML) UCART123 is an allogeneic CAR T-cell product candidate targeting CD123 and is being evaluated in patients with r/r AML in the AMELI-01 Phase 1 dose-escalation clinical study. On May 17, Cellectis presented an encore of the clinical data on the AMELI-01 clinical trial that were unveiled at the ASH 2022 annual meeting, at the American Society of Gene and Cell Therapy (ASGCT) 2023 annual meeting. These preliminary data support the continued administration of UCART123 after FCA lymphodepletion in patients with r/r AML. The oral presentation reviewed preliminary data from patients who received UCART123 at one of the following dose levels: dose level 1 (DL1) 2.5x105 cells/kg; dose level 2 (DL2) 6.25x105 cells/kg; intermediate dose level 2 (DL2i) 1.5x106 cells/kg; or dose level 3 (DL3) 3.30x106 cells/kg after lymphodepletion with FC ([n=8], DL1 – DL3) or FCA ([n=9], DL2 & DL2i). The data presented showed that adding alemtuzumab to the FC LD regimen was associated with sustained host lymphodepletion and significantly higher UCART123 cell expansion, that correlated with improved anti-tumor activity. 25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient who failed five prior lines of therapy including allogeneic stem cell transplant experienced a durable minimal residual disease (MRD)-negative complete response that continued beyond 12 months, as of December 2022. The AMELI-01 study is currently enrolling patients after FCA lymphodepletion in a two-dose regimen arm. Research Data & Preclinical Programs UCART20x22 On June 5, 2023, Cellectis presented preclinical data on its product candidate UCART20x22, at the International Society for Cell & Gene Therapy (ISCT) 2023 annual event. Cellectis provided pre-clinical proof-of-concept data for UCART20x22 to overcome current mechanisms of resistance to CAR T-cell therapies in B-NHL, while providing a potential therapeutic alternative to CD19 targeting and allowing a reduction in the time from treatment decision to infusion. Cellectis demonstrated that UCART20x22 displays robust activity in vitro and in vivo, against targets expressing heterogeneous levels of CD22 and CD20. We have used in vitro cytotoxicity assays against different tumor cell lines, showing strong activity whether these cells express a single antigen (CD20 or CD22) or both antigens simultaneously, as well as IFNg release in response to antigen specific stimulation. Article published in Cancer Immunology Research On May 31, 2023, Cellectis published an article in Cancer Immunology Research demonstrating pre-clinical proof-of-concept data of UCART20x22 product candidate, to overcome current mechanisms of resistance to CAR T-cell therapies in B-NHL. In this study, we demonstrated that allogeneic CD20x22 CAR T-cells exhibit robust, sustained and dose-dependent activity in vitro and in vivo, while efficiently targeting primary Non-Hodgkin Lymphoma samples with heterogeneous levels of CD20 and CD22. HBB gene correction of sickle cell mutation Encouraging preclinical data on gene editing process using Cellectis TALEN® technology to develop highly efficient HBB gene correction of sickle cell mutation, were presented in a poster presentation at the ISCT 2023 annual event. These results showed that non-viral DNA delivery associated with TALEN® gene editing reduces the toxicity usually observed with viral DNA delivery and allows high levels of HBB gene correction in long-term repopulating hematopoietic stem cells. Cellectis leveraged TALEN® technology to develop a gene editing process leading to highly efficient HBB gene correction via homology directed repair, while mitigating potential risks associated to HBB gene knock-out. Furthermore, we compared viral (TALEN-V) and non-viral (TALEN-NV) DNA template delivery strategies in mobilized healthy donor (HD) or non-mobilized homozygous sickle patient (HbSS) hematopoietic stem and progenitor cells (HSPCs). Both strategies led to high and comparable efficiencies of HBB gene correction in vitro in HD and HbSS, without affecting viability, purity or clonogenic potential of corrected HSPCs. The poster presentation highlighted the following data: TALEN®-mediated engineering efficiently corrects the mutated HBB gene in clinically relevant HSPCs and promote phenotype correction in fully mature RBCs. Cellectis optimized TALEN® gene editing process mitigates potential safety challenges by reducing the frequency of HBB gene inactivation (<10% β-thal cells). Non-viral DNA template-mediated HBB repair mitigates p53 DNA damage response activation, preserves edited LT-HSCs fitness and enables their efficient engraftment in vivo using an immunodeficient murine model. TALE Base Editors (TALE-BE) A comprehensive analysis to better design efficient TALE Base Editors (TALE-BE) using Cellectis’ TALEN® technology was presented in a poster at ISCT annual meeting. Cellectis developed a strategy that allowed to comprehensively characterize editing efficiencies in function of the TC position within the TALE-BE editing windows. This method is specifically taking advantage of the highly precise and efficient TALEN® mediated ssODN knock-in in primary T cells, allowing to focus on how target composition and spacer variations can affect TALE-BE activity/efficiency. The poster presentation highlighted the following data: Determined optimal spacer length (13/15 bp) for highly efficient TALE-BE for both C40/C40 and C11/C11 scaffolds. Determined optimal common sequence context for high editing rates. Determined that editing efficiency of the C11/C11 scaffold is highly dependent on Cytosine position requirements, resulting in more stringent activity in a context of 15 bp spacer size and decreasing the effects of bystander editing. We believe that the knowledge obtained will allow to better design efficient TALE-BE while improving the specificity profiles of this innovative editing platform. Novel treatment paradigm for successful CAR T immunotherapy against stroma-rich solid tumors On May 12, 2023, Cellectis published an article in Frontiers Bioengineering demonstrating the efficacy of its TALEN® engineered FAP UCART-cells in cancer-associated fibroblast (CAF) depletion, reduction of desmoplasia and tumor infiltration. Over 90% of epithelial cancers including breast, colorectal, pancreatic and lung adenocarcinomas express the CAF-specific surface marker, fibroblast activation protein α (FAP), which makes it a promising CAR T-cell target. In this study, Cellectis proposed a novel and versatile approach of combination CAR T-cell therapy that can be extended to most stroma-rich cold tumors with relevant tumor-antigen targeting CAR T-cells which otherwise are recalcitrant to cell therapy. Preclinical data showed that: In a mouse xenograft model, successful implantation of injected CAFs in the tumors was confirmed by positive staining of spindle-like cells with human-specific FAP antibody, recapitulating a physiologically relevant TNBC tumor with tumor and stromal compartments. FAP UCART-cells alone significantly reduced tumor growth. In vitro and in vivo results show that FAP UCART-cells enable the reprogramming of the cold, stroma-rich triple negative breast cancer (TNBC) TME, making the tumor susceptible to subsequent Meso UCART infiltration and cytotoxicity and improving the overall antitumor activity of the treatment. In the context of combination therapy with anti-PD1 checkpoint inhibitor, maximal anti-tumor activity and survival benefits were observed upon FAP UCART-cell treatment followed by Meso UCART-cell treatment. Licensed Allogeneic CAR T-cell Development Programs Servier and Allogene: anti-CD19 programs Allogene announced that it is enrolling patients “in the industry’s first potentially pivotal Phase 2 allogeneic CAR T clinical trial with ALLO-501A across sites in the United States and Canada”. The European Medicines Agency (EMA) recently approved the ALPHA2 Clinical Trial Application (CTA). Allogene’s single-arm ALPHA2 trial in relapsed/refractory (R/R) large B cell lymphoma (LBCL) will enroll approximately 100 patients who have received at least two prior lines of therapy and have not received prior anti-CD19 therapy. Allogene has announced that it expects to complete enrollment in 1H 2024 with the first data readout by the end of 2024. Long-term follow up data from the Phase 1 of Allogene’s ALPHA/ALPHA2 trials in LBCL was presented at both the American Society of Clinical Oncology (ASCO) Annual Meeting with an encore presentation at the European Hematology Association Congress and International Conference on Malignant Lymphoma (ICML) Lugano in June 2023. The Phase 1 trials enrolled heavily pre-treated patients with a median of three prior lines of therapy. Data from 33 CAR T-naïve LBCL patients receiving Alloy™ cell product including 12 patients treated with the Phase 2 regimen, are the first to demonstrate the potential for an allogeneic CAR T product to induce complete responses at rates and durability similar to approved autologous therapies. Allogene: anti-BCMA and anti-CD70 program The ongoing Phase 1 dose escalation of Allogene’s TRAVERSE study is enrolling patients with advanced or metastatic renal cell carcinoma (RCC) who have progressed on standard therapies including an immune checkpoint inhibitor and a VEGF-targeting therapy. Allogene’s TRAVERSE trial is now deploying an investigational in vitro companion diagnostic (IVD) assay designed to prospectively assess CD70 expression levels in patients. Allogene has announced that dose escalation in the TRAVERSE trial is expected to be completed in 2023. Corporate Updates On June 28, 2023, Cellectis reported results from the annual shareholders’ general meeting held on June 27, 2023, at the Company’s Paris headquarters. At the meeting, during which more than 72% of shares were exercised, Resolutions 1 through 28 were adopted and resolution 29 was rejected, according to the management recommendations. The detailed results of the vote and the resolutions are available on the company’s website: At the end of the meeting, the terms of office of Ms. Annick Schwebig and Mr. Hervé Hoppenot ended and Ms. Annick Schwebig and Mr. Hervé Hoppenot departed the board of directors as of such date. During the annual shareholders meeting, Cécile Chartier, Ph.D., was appointed as a director of the Cellectis’ Board of Directors, with immediate effect. Cécile Chartier currently serves as Chief Scientific Officer at NextVivo, Inc. Prior to her tenure at NextVivo, Dr. Chartier was Vice President of Research at Iovance Biotherapeutics, Inc. where she led the development of next generation tumor-infiltrating lymphocytes (TIL) therapies through research to early-stage clinical trials. Cécile’s extensive experience in the development of next generation cell and gene therapies coupled with her deep knowledge of the U.S. biotechnology industry will be a huge asset to Cellectis. Financial Results The interim condensed consolidated financial statements of Cellectis, have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board (“IFRS”). We present certain financial metrics broken out between our two reportable segments – Therapeutics and Plants – in the appendices of this Q2 2023 financial results press release. On January 13, 2023, Calyxt, Cibus Global LLC (Cibus) and certain other parties named therein, entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction (the “Calyxt Merger”). As a consequence of the foregoing, Calyxt met the “held-for-sale” criteria specified in IFRS 5 and was classified as a discontinued operation until May 31, 2023. On June 1, 2023, Calyxt and Cibus closed the merger transaction and now operate under the name Cibus, Inc. Consequently, Calyxt was deconsolidated and Calyxt’s cash, cash equivalent and restricted cash are no longer included in the Group’s cash, cash equivalent and restricted cash since June 1, 2023. Cash: As of June 30, 2023, Cellectis, had $89 million in consolidated cash, cash equivalents, and restricted cash. This compares to $95 million in consolidated cash, cash equivalents and restricted cash as of December 31, 2022. This $6 million difference mainly reflects $55 million of cash out, which include $15 million for R&D suppliers, $7 million for SG&A suppliers, $23 million for staff costs, $7 million for rents and taxes, $3 millions of reimbursement of the “PGE” loan, and a $1 million unfavorable impact on Forex partially offset by a $23 million net cash inflow from the capital raise closed in February, a $21 million net cash inflow from EIB loan, a $1 million cash inflow related to the grant and refundable advance from BPI, $2 millions of financial investments’ capital gain and interests, a $1 million reimbursement of social charges paid on stock options, and a $2 million net cash inflow from licenses and other cash receipts. Based on the current operating plan, Cellectis anticipates that the cash, cash equivalents, and restricted cash as of June 30, 2023 will fund Cellectis’ operations into the third quarter of 2024. Revenues and Other Income: Consolidated revenues and other income were $5.6 million for the six months ended June 30, 2023 compared to $6.5 million for the six months ended June 30, 2022. The decrease of $1.0 million reflects the recognition of two milestones related to Cellectis’ agreement with Cytovia for $1.5 million in 2022 and a milestone of $1.0 million with another partner while recognition of revenues in 2023 is not material, and partially offset by the increase of the research tax credit for $0.8 million and the partial recognition of a grant signed with “BPI” of $0.8 million. R&D Expenses: Consolidated R&D expenses were $43.2 million for the six months ended June 30, 2023, compared to $52.2 million for the six months ended June 30, 2022. The $9.0 million decrease was primarily attributable to (i) a $3.4 million decrease in personal expenses due to departures not replaced (ii) a $4.7 million decrease in purchases, external expenses and other (from $28.0 million in 2022 to $23.2 million in 2023) mainly explained by internalization of our manufacturing and quality activities to support our R&D pipeline and (iii) a $0.8 million decrease of non-cash stock-based compensation expenses (from $3.1 million to $2.3 million). SG&A Expenses: Consolidated SG&A expenses were $8.9 million for the six months ended June 30, 2023, compared to $10.9 million for the six months ended June 30, 2022. The $2.0 million decrease primarily reflects (i) a $1.6 million decrease in purchases, external expenses and other (from $6.4 million in 2022 to $4.9 million in 2023) mainly explained by the implementation of our ERP in 2022 (ii) a $0.2 million decrease in personal expenses and non-cash stock-based compensation expenses. Net financial gain (loss): Consolidated net financial gain was $11.6 million for the six months ended June 30, 2023, compared to $9.2 million for the six months ended June 30, 2022. The $2.4 million increase primarily reflects (i) a $20.8 million increase of financial income, mainly attributable to the profit from Calyxt’s deconsolidation, partially offset by (ii) the loss in fair value on our retained investment in Calyxt since deconsolidation for $10.2 million, (iii) a $6.8 million decrease in the fair value of Cytovia’s note receivable. Net income (loss) from discontinued operations: Pursuant to Calyxt deconsolidation income from discontinued operation for the six-month period ended June 30, 2023, 2023 only include five months of activity. The $3.5 million increase of net loss from discontinued operations between the six-month period ended June 30, 2022 and 2023 is primarily driven by (i) the increase of $9.2 million of net financial loss and (ii) the increase of $1.5 million of other operating expenses partially offset by (i) the decrease of $2.8 million of R&D expenses (from $6.3 million in 2022 to $3.5 in 2023) and (ii) the decrease of $4.5 million of SG&A expenses (from $6.8 million in 2022 to $2.3 million in 2023). Net Income (loss) Attributable to Shareholders of Cellectis: The consolidated net loss attributable to shareholders of Cellectis was $40.7 million (or $0.76 per share) for the six months ended June 30, 2023, of which $35.7 million was attributed to Cellectis continuing operations, compared to $50.9 million (or $1.12 per share) for the six months ended June 30, 2022, of which $47.3 million was attributed to Cellectis continuing operations. This $10.1 million decrease in net loss between the first six months of 2023 and 2022 was primarily driven by (i) a $9.0 million decrease of R&D expenses, (ii) a $2.0 million decrease of SG&A expenses and (iii) an increase of $2.4 million of the financial gain due to the deconsolidation of Calyxt compensated in part by the decrease of fair value of Cytovia’s note receivable. These downward impacts on the net loss were partially offset by (i) a decrease of $1.0 million of revenues and other income, (ii) an increase of $1.5 million of loss from discontinued operations attributable to Shareholders of Cellectis. Adjusted Net Income (Loss) Attributable to Shareholders of Cellectis: The consolidated adjusted net loss attributable to shareholders of Cellectis was $36.7 million (or $0.68 per share) for the six months ended June 30, 2023, compared to a net loss of $45.5 million (or $1.00 per share) for the six months ended June 30, 2022. Please see “Note Regarding Use of Non-IFRS Financial Measures” for reconciliation of GAAP net income (loss) attributable to shareholders of Cellectis to adjusted net income (loss) attributable to shareholders of Cellectis. We currently foresee focusing our cash spending at Cellectis for 2023 in the following areas: Supporting the development of our pipeline of product candidates, including the manufacturing and clinical trial expenses of UCART123, UCART22, UCART 20x22 and potential new product candidates; Operating our state-of-the-art manufacturing capabilities in Paris (France), and Raleigh (North Carolina, USA); and Continuing to strengthen our manufacturing and clinical departments. The selected, preliminary financial information set forth above are unaudited and should be considered preliminary and subject to change. We have provided such selected, preliminary results above as our final results remain subject to the completion of our normal closing procedures, final adjustments, developments that may arise between now and the time the financial results are finalized, and management’s and the audit and finances committee’s final reviews. Accordingly, you should not place undue reliance on this preliminary information, which may differ materially from our actual final results. These preliminary results should not be viewed as a substitute for our full quarterly financial statements prepared in accordance with IFRS. In addition, they are not necessarily indicative of the results to be achieved in any future period. These preliminary results have been prepared by and are the responsibility of management. Our independent registered public accounting firm has not audited, compiled, performed any procedures on or revised the preliminary financial information, and accordingly does not express an opinion or any other form of assurance with respect of the preliminary information. We plan to report our full results for the second quarter in the coming days. CELLECTIS S.A. STATEMENT OF CONSOLIDATED FINANCIAL POSITION(unaudited) ($ in thousands) As of December 31, 2022 June 30, 2023 ASSETS Non-current assets Intangible assets 718 695 Property, plant, and equipment 63,621 59,231 Right-of-use assets 44,275 41,457 Non-current financial assets 8,791 13,006 Total non-current assets 117,406 114,389 Current assets Trade receivables 772 422 Subsidies receivables 14,496 19,488 Other current assets 9,078 7,869 Cash and cash equivalent and Current financial assets 97,697 85,505 Total current assets 122,043 113,285 Total assets held for sale 21,768 0 TOTAL ASSETS 261,216 227,674 LIABILITIES Shareholders’ equity Share capital 2,955 3,491 Premiums related to the share capital 583,122 476,224 Currency translation adjustment (28,605 ) (37,050 ) Retained earnings (333,365 ) (305,392 ) Net income (loss) (106,139 ) (40,715 ) Total shareholders’ equity - Group Share 117,968 96,558 Non-controlling interests 7,973 0 Total shareholders’ equity 125,941 96,558 Non-current liabilities Non-current financial liabilities 20,531 40,270 Non-current lease debts 49,358 46,157 Non-current provisions 2,390 2,641 Total non-current liabilities 72,279 89,068 Current liabilities Current financial liabilities 5,088 5,185 Current lease debts 7,872 8,270 Trade payables 21,456 19,229 Deferred revenues and deferred income 59 241 Current provisions 477 1,029 Other current liabilities 13,179 8,093 Total current liabilities 48,131 42,047 Total liabilities related to asset held for sale 14,864 0 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 261,216 227,674 Cellectis S.A. UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS For the three-month period ended June 30, 2023 $ in thousands, except per share amounts For the three-month period ended June 30, 2022 * 2023 Revenues and other income Revenues 1,307 178 Other income 1,416 1,823 Total revenues and other income 2,723 2,001 Operating expenses Cost of revenue (329 ) (55 ) Research and development expenses (25,630 ) (22,144 ) Selling, general and administrative expenses (4,830 ) (3,950 ) Other operating income (expenses) 753 490 Total operating expenses (30,036 ) (25,660 ) Operating income (loss) (27,313 ) (23,659 ) Financial gain (loss) 8,301 15,982 Income tax 0 (258 ) Income (loss) from continuing operations (19,012 ) (7,935 ) Income (loss) from discontinued operations (442 ) (5,647 ) Net income (loss) (19,454 ) (13,583 ) Attributable to shareholders of Cellectis (18,946 ) (10,648 ) Attributable to non-controlling interests (506 ) (2,935 ) Basic net income (loss) attributable to shareholders of Cellectis per share ($/share) (0.42 ) (0.19 ) Diluted net income (loss) attributable to shareholders of Cellectis per share ($/share) (0.42 ) (0.19 ) Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations 0.00 (0.05 ) Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations 0.00 (0.05 ) * These amounts reflect adjustments made in connection with the presentation of the discontinued operation CELLECTIS S.A. UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS For the six-month period ended June 30, 2023 $ in thousands, except per share amounts For the six-month period ended June 30, 2022 * 2023 Revenues and other income Revenues 2,972 317 Other income 3,551 5,242 Total revenues and other income 6,523 5,560 Operating expenses Cost of revenue (714 ) (389 ) Research and development expenses (52,231 ) (43,225 ) Selling, general and administrative expenses (10,893 ) (8,914 ) Other operating income (expenses) 774 (83 ) Total operating expenses (63,064 ) (52,612 ) Operating income (loss) (56,541 ) (47,053 ) Financial gain (loss) 9,213 11,580 Income tax 0 (258 ) Income (loss) from continuing operations (47,328 ) (35,731 ) Income (loss) from discontinued operations (6,883 ) (10,377 ) Net income (loss) (54,211 ) (46.108 ) Attributable to shareholders of Cellectis (50,858 ) (40,715 ) Attributable to non-controlling interests (3,352 ) (5,393 ) Basic net income (loss) attributable to shareholders of Cellectis per share ($/share) (1.12 ) (0.76 ) Diluted net income (loss) attributable to shareholders of Cellectis per share ($/share) (1.12 ) (0.76 ) Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations (0.08 ) (0.09 ) Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations (0.08 ) (0.09 ) * These amounts reflect adjustments made in connection with the presentation of the discontinued operation CELLECTIS S.A. DETAILS OF KEY PERFORMANCE INDICATORS BY REPORTABLE SEGMENTS – For the three-month period ended June 30, 2023 (unaudited) - ($ in thousands) For the three-month period ended June 30, 2022 For the three-month period ended June 30, 2023 $ in thousands Plants (discontinued operations) Therapeutics Total reportable segments Plants (discontinued operations) Therapeutics Total reportable segments External revenues 42 1,307 1,348 1 178 179 External other income - 1,416 1,416 - 1,823 1,823 External revenues and other income 42 2,723 2,765 1 2,001 2,002 Cost of revenue 0 (329 ) (329 ) (63 ) (55 ) (118 ) Research and development expenses (3,419 ) (25,630 ) (29,048 ) (1,322 ) (22,144 ) (23,467 ) Selling, general and administrative expenses (3,585 ) (4,830 ) (8,415 ) (976 ) (3,950 ) (4,927 ) Other operating income and expenses 198 753 951 (1,074 ) 490 (584 ) Total operating expenses (6,806 ) (30,036 ) (36,842 ) (3,435 ) (25,660 ) (29,095 ) Operating income (loss) before tax (6,764 ) (27,313 ) (34,077 ) (3,434 ) (23,659 ) (27,093 ) Financial gain (loss) 6,322 8,301 14,623 (2,213 ) 15,982 13,769 Income tax - - - - (258 ) (258 ) Net income (loss) from discontinued operations (442 ) (442 ) (5,647 ) (5,647 ) Net income (loss) (442 ) (19,012 ) (19,454 ) (5,647 ) (7,935 ) (13,583 ) Non controlling interests 506 - 506 (2,935 ) - (2,935 ) Net income (loss) attributable to shareholders of Cellectis 64 (19,012 ) (18,946 ) (2,712 ) (7,935 ) (10,648 ) R&D non-cash stock-based expense attributable to shareholder of Cellectis 226 1,454 1,681 103 797 900 SG&A non-cash stock-based expense attributable to shareholder of Cellectis 447 557 1,003 326 849 1,174 Adjustment of share-based compensation attributable to shareholders of Cellectis 673 2,011 2,684 428 1,646 2,074 Adjusted net income (loss) attributable to shareholders of Cellectis 737 (17,001 ) (16,264 ) (2,284 ) (6,289 ) (8,573 ) Depreciation and amortization (608 ) (4,500 ) (5,108 ) (12 ) (4,419 ) (4,431 ) Additions to tangible and intangible assets 308 870 1,178 21 311 332 CELLECTIS S.A. DETAILS OF KEY PERFORMANCE INDICATORS BY REPORTABLE SEGMENTS – For the six-month period ended June 30, 2023 (unaudited) - ($ in thousands) For the six-month period ended June 30, 2022 For the six-month period ended June 30, 2023 $ in thousands Plants (discontinued operations) Therapeutics Total reportable segments Plants (discontinued operations) Therapeutics Total reportable segments External revenues 73 2,972 3,045 43 317 360 External other income - 3,551 3,551 - 5,242 5,242 External revenues and other income 73 6,523 6,596 43 5,560 5,602 Cost of revenue (0 ) (714 ) (714 ) (63 ) (389 ) (451 ) Research and development expenses (6,297 ) (52,231 ) (58,527 ) (3,487 ) (43,225 ) (46,712 ) Selling, general and administrative expenses (6,801 ) (10,893 ) (17,695 ) (2,313 ) (8,914 ) (11,227 ) Other operating income and expenses 242 774 1,016 (1,251 ) (83 ) (1,334 ) Total operating expenses (12,856 ) (63,064 ) (75,920 ) (7,113 ) (52,612 ) (59,725 ) Operating income (loss) before tax (12,783 ) (56,541 ) (69,324 ) (7,070 ) (47,053 ) (54,123 ) Net financial gain (loss) 5,900 9,213 15,113 (3,307 ) 11,580 8,273 Income tax - - - - (258 ) (258 ) Net income (loss) from discontinued operations (6,883 ) (6,883 ) (10,377 ) (10,377 ) Net income (loss) (6,883 ) (47,328 ) (54,211 ) (10,377 ) (35,731 ) (46,108 ) Non-controlling interests 3,352 - 3,352 5,393 - 5,393 Net income (loss) attributable to shareholders of Cellectis (3,531 ) (47,328 ) (50,858 ) (4,984 ) (35,731 ) (40,715 ) R&D non-cash stock-based expense attributable to shareholder of Cellectis 216 3,134 3,349 188 1,900 2,088 SG&A non-cash stock-based expense attributable to shareholder of Cellectis 789 1,193 1,982 599 1,366 1,965 Adjustment of share-based compensation attributable to shareholders of Cellectis 1,005 4,327 5,331 788 3,265 4,053 Adjusted net income (loss) attributable to shareholders of Cellectis (2,526 ) (43,001 ) (45,527 ) (4,196 ) (32,465 ) (36,663 ) Depreciation and amortization (1,316 ) (9,434 ) (10,749 ) (7 ) (8,875 ) (8,882 ) Additions to tangible and intangible assets 671 1,452 2,123 21 536 556 Note Regarding Use of Non-IFRS Financial Measures Cellectis S.A. presents adjusted net income (loss) attributable to shareholders of Cellectis in this press release. Adjusted net income (loss) attributable to shareholders of Cellectis is not a measure calculated in accordance with IFRS. We have included in this press release a reconciliation of this figure to net income (loss) attributable to shareholders of Cellectis, which is the most directly comparable financial measure calculated in accordance with IFRS. Because adjusted net income (loss) attributable to shareholders of Cellectis excludes Non-cash stock-based compensation expense—a non-cash expense, we believe that this financial measure, when considered together with our IFRS financial statements, can enhance an overall understanding of Cellectis’ financial performance. Moreover, our management views the Company’s operations, and manages its business, based, in part, on this financial measure. In particular, we believe that the elimination of Non-cash stock-based expenses from Net income (loss) attributable to shareholders of Cellectis can provide a useful measure for period-to-period comparisons of our core businesses. Our use of adjusted net income (loss) attributable to shareholders of Cellectis has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under IFRS. Some of these limitations are: (a) other companies, including companies in our industry which use similar stock-based compensation, may address the impact of Non-cash stock- based compensation expense differently; and (b) other companies may report adjusted net income (loss) attributable to shareholders or similarly titled measures but calculate them differently, which reduces their usefulness as a comparative measure. Because of these and other limitations, you should consider adjusted net income (loss) attributable to shareholders of Cellectis alongside our IFRS financial results, including Net income (loss) attributable to shareholders of Cellectis. RECONCILIATION OF IFRS TO NON-IFRS NET INCOME For the three-month period ended June 30, 2023 (unaudited) - ($ in thousands except per share data) For the three-month period ended June 30, 2022 * 2023 Net income (loss) attributable to shareholders of Cellectis (18,946 ) (10,648 ) Adjustment: Non-cash stock-based compensation expense attributable to shareholders of Cellectis 2,684 2,074 Adjusted net income (loss) attributable to shareholders of Cellectis (16,263 ) (8,574 ) Basic Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (0.36 ) (0.15 ) Basic adjusted earnings from discontinued operations attributable to shareholders of Cellectis ($ /share) 0.00 (0.05 ) Weighted average number of outstanding shares, basic (units) 45,497,127 55,583,768 Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1) (0.36 ) (0.15 ) Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) from discontinued operations 0.02 (0.04 ) Weighted average number of outstanding shares, diluted (units) 45,497,127 55,583,768 *These amounts reflect adjustments made in connection with the presentation of the discontinued operation RECONCILIATION OF IFRS TO NON-IFRS NET INCOME (unaudited) First six months ($ in thousands, except per share data) For the six-month period ended June 30, 2022 * 2023 Net income (loss) attributable to shareholders of Cellectis (50,858 ) (40,715 ) Adjustment: Non-cash stock-based compensation expense attributable to shareholders of Cellectis 5,331 4,053 Adjusted net income (loss) attributable to shareholders of Cellectis (45,527 ) (36,662 ) Basic Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1.00 ) (0.68 ) Basic adjusted earnings from discontinued operations attributable to shareholders of Cellectis ($ /share) (0.95 ) (0.71 ) Weighted average number of outstanding shares, basic (units) 45,497,127 53,541,010 Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1.00 ) (0.68 ) Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) from discontinued operations (0.95 ) (0.71 ) Weighted average number of outstanding shares, diluted (units) 45,497,127 53,541,010 *These amounts reflect adjustments made in connection with the presentation of the discontinued operation About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 23 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). Forward-looking Statements This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate”, “expect”, “plan”, “could” and “will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners. Forward-looking statements include statements about advancement, timing and progress of clinical trials and preclinical studies, the timing of our presentation of data, and the sufficiency of cash to fund operation. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2022 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Investor Relations contacts: Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577 1 Cash position includes cash, cash equivalents and restricted cash. Restricted cash was $5 million as of June 30, 2023. 2 This project is partially funded by the French government, as part of Plan France 2030. On March 8, 2023, BPIfrance and Cellectis entered into a grant and refundable advance agreement to partially support research and development program related to UCART20x22. Attachment Press release earnings Q22023